Definium Therapeutics (DFTX) Share-based Compensation (2021 - 2026)

Definium Therapeutics (DFTX) has reported Share-based Compensation for 6 consecutive years, with $11.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Share-based Compensation rose 235.08% year-over-year to $11.5 million; the TTM figure through Mar 2026 stood at $25.0 million (up 96.71% YoY), while the FY2025 annual figure was $5.9 million, up 10892.59% from the prior year.
• Share-based Compensation improved to $11.5 million in Q1 2026 per DFTX's latest filing, from $2.4 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $11.5 million in Q1 2026 and bottomed at $64000.0 in Q4 2023.
• Historically, Share-based Compensation has averaged $4.1 million across 5 years, with a median of $3.8 million in 2023.
• Annual changes were most pronounced in 2023 — Share-based Compensation sank 95.35% — and 2026, when it jumped 235.08%.
• Definium Therapeutics' Share-based Compensation stood at $1.4 million in 2022, then tumbled by 95.35% to $64000.0 in 2023, then soared by 5901.56% to $3.8 million in 2024, then sank by 36.81% to $2.4 million in 2025, then surged by 373.01% to $11.5 million in 2026.
• Business Quant data shows DFTX's Share-based Compensation at $11.5 million in Q1 2026, $2.4 million in Q4 2025, and $5.8 million in Q3 2025.